Hemato Oncology Testing Market Size Worth $7.2 Billion By 2027

October 2020 | Report Format: Electronic (PDF)

Hemato Oncology Testing Market Growth & Trends

The global hemato oncology testing market size is expected to reach USD 7.2 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 14.6% from 2020 to 2027. Key drivers for the market include rising incidences of leukemia, lymphoma, myeloproliferative neoplasms, and multiple myeloma. Also, growing collaborations among various major players and research organizations, and an increasing number of research activities conducted by academic and research institutes to develop technologically advanced hemato oncology tests is anticipated to fuel market growth.

The rising prevalence of lymphoma and myeloma is anticipated to propel the market growth during the forecast period. According to a report published by the American Cancer Society, it is estimated that there over 32,270 new cases of multiple myeloma which included 14,740 women and 17,530 men in 2018. Whereas, over 12,830 deaths were recorded in 2018 that included 5,640 women and 7,190 men. Therefore, a rise in the prevalence of the above-mentioned diseases is expected to enhance the usage of hemato oncology testing products.

An increase in the number of product launches is also a major factor contributing to the growth of the market. For instance, in October 2018, MedGenome launched the IGHV gene mutation testing. This test enables health care professionals to access the prognosis of chronic lymphocytic leukemia, and further manage the disease by personalized therapy.

The FDA approval of Invivoscribe’s LeukoStrat companion diagnostic test in conjugation with Novartis’s Rydapt for detection and treatment of AML has been a key factor in the rising number of manufacturers opting for the development of related products. The CE approved assay was launched in 2017, being the first companion diagnostic to be used for the detection of AML. Similarly, in the year 2018, Invivoscribe announced the U.S. FDA's approval for LeukoStrat CDx FLT3 Mutation Assay and XOSPATA, an AML drug manufactured by Astellas Pharma.

Growing collaborations among market players and academic and research organizations are anticipated to boost growth during the forecast period. For instance, in May 2018, Invivoscribe Technologies Inc. collaborated with the American University of Beirut Medical Center (AUBMC) in order to design and build a new center for excellence treatment in the Middle East region for advanced research in hemato oncology testing as well as treatment.

 Request a free sample copy or view report summary: Hemato Oncology Testing Market Report

Hemato Oncology Testing Market Report Highlights

  • Lymphoma held a dominant share in terms of revenue in the cancer type segment owing to a rise in the prevalence of Hodgkin and Non-Hodgkin Lymphoma

  • The services segment captured the largest market share due to an increase in the incidence rate and rising awareness regarding various treatment therapies such as personalized medicines

  • The PCR segment dominated the market in terms of revenue share in 2019 and witnessed exponential growth owing to its ease in use, affordability, the accuracy and efficiency provided, rise in the number of product launches and approval, technological advancements of testing products, and easy availability

  • The hospitals segment witnessed exponential growth in 2019 owing to the availability of hemato oncology diagnostic tests and the presence of healthcare professionals to conduct diagnostic tests and monitor the disease

  • In North America, the market is expected to witness exponential growth during the forecast period owing to a rise in the prevalence of multiple myeloma, the growing number of awareness and screening campaigns, and the launch of technologically advanced products for the diagnosis of hemato oncology

Hemato Oncology Testing Market Segmentation

Grand View Research has segmented the global hemato oncology testing market report on the basis of cancer type, product, technology, end-use, and region:

Hemato Oncology Testing Cancer Type Outlook (Revenue, USD Million, 2016 - 2027)

  • Leukemia

    • Acute Myeloid Leukemia (AML)

    • Acute Lymphocytic Leukemia (ALL)

    • Chronic Lymphocytic Leukemia

    • Chronic Myeloid Leukemia

  • Lymphoma

    • Non-Hodgkin Lymphoma

    • Hodgkin Lymphoma

  • Myeloproliferative Neoplasms

    • Polycythemia vera (PV)

    • Essential thrombocythemia (ET)

    • Myelofibrosis (MF)

  • Other Cancers

Hemato Oncology Testing Product Outlook (Revenue, USD Million, 2016 - 2027)

  • Assay Kits and Reagents

  • Services

Hemato Oncology Testing Technology Outlook (Revenue, USD Million, 2016 - 2027)

  • PCR

    • Real-time qPCR

    • Digital PCR

  • IHC

  • NGS

  • Cytogenetics

  • Other Technologies

Hemato Oncology Testing End-use Outlook (Revenue, USD Million, 2016 - 2027)

  • Hospitals

  • Academic & Research Institutes

  • Others

Hemato Oncology Testing Regional Outlook (Revenue, USD Million, 2016 - 2027)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Russia

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Singapore

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

List of Key Players of Hemato Oncology Testing Market

  • F. Hoffman-La Roche Ltd

  • Abbott Laboratories

  • EntroGen, Inc.

  • Qiagen N.V.

  • Cepheid

  • Thermo Fisher Scientific, Inc.

  • Bio-Rad Laboratories, Inc.

  • Illumina, Inc.

Pricing & Purchase Options

Service Guarantee

Buy Chapters or Sections

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Related Market Research